ALX Oncology raises $105 million in Series C financing for CD47 trials

By Akshay Kedari  | Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Instagram users can now delete their accounts on all Apple devices

Instagram users can now delete their accounts on all Apple devices

By Akshay Kedari

To comply with Apple’s App Store guidelines, popular social media platform Instagram has now added account deletion support to iOS devices. The iPhone maker's store policy notably instructs that all apps that allow users to create accounts ...

Tesla lays off 200 hourly workers as it closes its California office

Tesla lays off 200 hourly workers as it closes its California office

By Akshay Kedari

Tesla Inc. reportedly closed its San Mateo, California office to expedite cost-cutting and has let go nearly 200 workers who functioned on its autopilot driver-assistant system. Most of these employees were compensated on an hourly basis. Earlier ...

Around 2,900 Ford Lightning pickups recalled over software-linked issue

Around 2,900 Ford Lightning pickups recalled over software-linked issue

By Akshay Kedari

The recall covers 220 units of the electric pickup trucks in Canada and 2,666 units in the US. Ford has refused to accept any more orders and declared the EV sold out for 2022. Ford Motor Company has reportedly recalled the first batch of ...

Coca-Cola ranked the most powerful brand in U.S., as per the BSI score

Coca-Cola ranked the most powerful brand in U.S., as per the BSI score

By Akshay Kedari

The Coca-Cola Company, an American multinational beverage corporation, has reportedly secured a Brand Strength Index (BSI) score of 93.3 out of 100, making it the strongest brand in the USA, according to a TradingPlatforms.com analysis of the iconic ...

FDA to order Juul Labs to pull its e-cigarettes from the United States

FDA to order Juul Labs to pull its e-cigarettes from the United States

By Akshay Kedari

The U.S. FDA (Food and Drug Administration) is reportedly planning to instruct Juul Labs Inc. to stop supplying its e-cigarettes in the country. Shares of Altira, which owns a 35% stake in Juul Labs, fell to 8.5% after the latest development. For ...